Cyrus L. Harmon

Cyrus L. Harmon

DirectoratOlema Pharmaceuticals· In proxies 2023–2025

Pay in FY2023Olema Pharmaceuticals stock +472.7% the same year

Cyrus L. Harmon was paid $1.3M in FY2023 (Dec). Olema Pharmaceuticals stock rose 472.7% that year.

Pay$100 in the stock at the end of FY22 → $573
Pay is from the Summary Compensation Table of each Olema Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Olema PharmaceuticalsPublic company · 3 yr
    • Director2023 – Present · 3 yrStock in role +191%
  2. Akero Therapeutics, Inc.Public company · 8 yr
    • Director2018 – Present · 8 yrNo stock prices for these years
  3. ALX Oncology Holdings Inc.Public company · 1 yr
    • Director2020 – 2021 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Olema PharmaceuticalsDirector · 19 yr on the boardIndependentScience and Technology—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?